Apogee Therapeutics (APGE) EBITDA (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of EBITDA data on file, last reported at -$82.8 million in Q1 2026.

• On a quarterly basis, EBITDA fell 31.18% year-over-year to -$82.8 million in Q1 2026; TTM through Mar 2026 was -$305.3 million, a 26.26% decrease from a year earlier, with the FY2025 full-year figure at -$285.6 million, down 31.69% from the prior year.
• EBITDA for Q1 2026 stood at -$82.8 million, down from -$78.1 million in the prior quarter.
• Over the last five years, EBITDA for APGE reached as high as -$1.8 million in Q2 2022 and fell as low as -$82.8 million in Q1 2026.
• Historically, EBITDA has averaged -$44.0 million across 5 years, with a median of -$41.2 million in 2024.
• Across the five-year window, EBITDA slumped 939.92% in 2023 and fell 2.87% in 2025, its largest moves.
• Year by year, EBITDA stood at -$14.1 million in 2022, then tumbled by 163.53% to -$37.2 million in 2023, then sank by 104.23% to -$75.9 million in 2024, then decreased by 2.87% to -$78.1 million in 2025, then retreated by 6.04% to -$82.8 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$82.8 million in Q1 2026, -$78.1 million in Q4 2025, and -$71.3 million in Q3 2025.